Skip to main navigation Skip to search Skip to main content

Additional file 5 of Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

  • Osman Öcal (Creator)
  • Regina Schinner (Creator)
  • Kerstin Schütte (Creator)
  • Enrico N. De Toni (Creator)
  • Christian Loewe (Creator)
  • Otto van Delden (Creator)
  • Vincent Vandecaveye (Creator)
  • Bernhard Gebauer (Creator)
  • Christoph J Zech (Creator)
  • Christian Sengel (Creator)
  • Irene Bargellini (Creator)
  • Antonio Gasbarrini (Creator)
  • Bruno Sangro (Creator)
  • Maciej Pech (Creator)
  • Peter Malfertheiner (Creator)
  • Jens Ricke (Creator)
  • Max Seidensticker (Creator)

Dataset

Description

Additional file 5: Supplementary Fig. 5. Overall survival of patients according to best response. BR, best response; CI, confidence interval; CR, complete response; HR, hazard ratio; PR, partial response; PD, progressive disease; SD, stable disease.
Date made available2022
Publisherfigshare

Access Dataset

Cite this